The endocrine system in chronic nitric oxide deficiency

European Journal of Endocrinology

Volumn 156, Issue 1, 2007, Pages 1-12

  Vargas, Félix ^d   Moreno, Juan Manuel ^a   Wangensteen, Rosemary ^b   Rodríquez Gómez, Isabel ^d   Garcia Estan, Joaquín ^c  

^a Hospital Virgen de las Nievas   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

^d UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ADRENALIN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ARACHIDONIC ACID; BEZAFIBRATE; BOSENTAN; CATECHOLAMINE; CYTOCHROME P450; DEOXYCORTICOSTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ESTROGEN; INDOMETACIN; LEPTIN; LOSARTAN; MINERALOCORTICOID; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN; OMAPATRILAT; PRAZOSIN; PROSTAGLANDIN E2; RENIN; TESTOSTERONE; THIAMAZOLE; THYROID HORMONE; UNINDEXED DRUG; VASOPRESSIN; HORMONE;

ANTIHYPERTENSIVE ACTIVITY; ARACHIDONIC ACID METABOLISM; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; DISEASE ASSOCIATION; DRUG MECHANISM; ENDOCRINE FUNCTION; ENDOTHELIAL DYSFUNCTION; HORMONAL REGULATION; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PRESSOR RESPONSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SEX DIFFERENCE; SODIUM RETENTION; VASCULAR ENDOTHELIUM; ANIMAL; ARTICLE; BLOOD PRESSURE; ENDOCRINE SYSTEM; PHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; ENDOCRINE SYSTEM; HORMONES; HUMANS; HYPERTENSION; NITRIC OXIDE;

EID: 33847711873     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02314     Document Type: Review

References (144)

1. Zatz R & Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 1998 32 958-964.
2. Arnal JF, Dinh-Xuan AT, Pueyo M, Darblade B & Rami J. Endothelium-derived nitric oxide and vascular physiology and pathology. Cellular and Molecular Life Sciences 1999 55 1078-1087.
3. Kunes J, Hojna S, Kadlecova M, Dobesova Z, Rauchova H, Vokurkova M, Loukotova J, Pechanova O & Zicha J. Altered balance of vasoactive systems in experimental hypertension: the role of relative NO deficiency. Physiological Research 2004 53 (Suppl) S23-S34.
4. Vidal MJ, Romero JC & Vanhoutte PM. Endothelium-derived relaxing factor inhibits renin release. European Journal of Pharmacology 1988 149 401-402.
5. Greenberg SG, He XR, Schnermann JB & Briggs JP. Effect of nitric oxide on renin secretion. 1. Studies in isolated juxtaglomerular granular cells. American Journal of Physiology 1995 268 F948-F952.
6. Tharaux PL, Dussaule JC, Pauti MD, Vassitch Y, Ardaillou R & Chatziantoniou C. Activation of renin synthesis is dependent on intact nitric oxide production. Kidney International 1997 51 1780-1787.
7. Gardes J, Gonzalez ME, Alhenc-Gelas F & Menard J. Influence of sodium diet on L-NAME effects on renin release and renal vasoconstriction. American Journal of Physiology 1994 267 F798-F804.
8. Braam B. Renal endothelial and macula densa NOS: integrated response to changes in extracellular fluid volume. American Journal of Physiology 1999 276 R1551-111561.
9. Zanchi A, Schaad NC, Osterheld MC, Grouzmann E, Nussberger J, Brunner HR & Waeber B. Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. American Journal of Physiology 1995 268 H2267-H2273.
10. Braam Singh IM, Grams M, Wang WH, Yang T, Killen P, Smart A, Schnermann J & Brigss JP. Coordinated regulation of renal expression of nitric oxide synthase, renin and angiotensinogen mRNA by dietary salt. American Journal of Physiology 1996 270 F1027-F1037.
11. Braam Persson PB, Baumann JE, Ehmke H, Hackenthal HR, Kirchheim HR & Nafz B. Endothelium-derived NO stimulates pressure - dependent renin release in conscious dogs. American Journal of Physiology 1993 264 F943-F947.
12. Braam Beierwaltes WH. Selective neuronal nitric oxide synthase inhibition blocks furosemide-stimulated renin secretion in vivo. American Journal of Physiology 1995 269 F134-F139.
13. Wangensteen R, Sainz J, Rodríguez-Gómez I, Moreno JM, Osuna A & Vargas F. Chronic blockade of neuronal nitric oxide synthase does not affect long-term control of blood pressure in normal, saline-drinking or deoxycorticosterone-treated rats. Experimental Physiology 2003 88 243-250.
14. Ollerstam A, Skott O, Ek J, Persson AEG & Thorup C. Effects of long-term inhibition of neurorial nitric oxide synthase on blood pressure and renin release. Acta Physiologica Scandinavica 2001 173 351-358.
15. Raij L. Hypertension and cardiovascular risk factors. Role of the Anglotensin II-nitric oxide interaction. Hypertension 2001 37 767-773.
16. Millatt LJ, Abdel-Rahman EM & Siragy HM. Angiotensin II and nitric oxide: a question of balance. Regulatory Peptides 1999 81 1-10.
17. Bank N, Aynedjian HS & Khan GA. Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats. Hypertension 1994 24 322-328.
18. Qiu C, Engels K & Baylis C. Angiotensin II and alpha 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension. American Journal of Physiology 1994 266 R1470-Rl476.
19. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM & Zatz R. Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension 1992 20 298-303.
20. Jover B, Herizi A, Ventre F, Dupont M & Mimran A. Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension 1993 21 944-948.
21. De Gracia MC, Osuna A, O'Valle F, Del Moral RG, Wangensteen R, García del Río C & Vargas F. Deoxycorticosterone suppresses the effects of losartan in nitric oxide-deficient hypertensive rats. Journal of the American Society of Nephrology 2000 11 1995-2000.
22. Fortepiani LA, Rodrigo E, Ortiz MC, Cachofeiro V, Atucha NM, Ruilope LM, Lahera V & Garcia-Estan J. Pressure natriuresis in nitric oxide-deficient hypertensive rats: effect of antihypertensive treatments. Journal of the American Society of Nephrology 1999 10 21-27.
23. Pollock DM, Polakowski JS, Divish BJ & Opgenorth TJ. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 1993 21 660-666.
24. Morton JJ, Beattie EC, Speirs A & Gulliver F. Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy, Journal of Hypertension 1993 11 1083-1088.
25. Burnett JC, Jr. Vasopeptidase inhibition: a new concept in blood pressure management. Journal of Hypertension 1999 17 S37-S43.
26. Burrell LM, Rockell MD, Powell J & Johnston CI. In vivo inhibition of angiotensin converting enzyme and neutral endopeptidase by a dual vasopeptidase inhibitor. American Journal of Hypertension 1999 12 (Suppl 1) 119.
27. Trippodo NC, Rohl JA, Asaad MM, Fox M, Panchal BC & Schaeffer TR. Effects of omapatrilat in low, normal and high renin experimental hypertension. American Journal of Hypertension 1998 11 363-372.
28. d'Uscio LV, Quaschning T, Burmett JC, Jr & Luscher TF. Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition. Hypertension 2001 37 28-33.
29. Kuro T, Okahara A, Nose M, Ikuse T & Matsumura Y. Effects of SA7060, a novel dual inhibitor of neutral endopeptidasc and angiotensin-converting enzyme, on deoxycorticosteronc acetate-salt-induced hypertension in rats. Biological and Pharmaceutical Bulletin 2000 23 820-825.
30. Zhu ST, Chen YF, Oparil S & Calhoun DA. Omapatrilat, a vasopeptidase inhibitor, enhances baroreflex gain in spontaneously hypertensive rats. Journal of Hypertension 1999 17 S65.
31. Rodríguez-Gomez I, Wangensteen R, Atucha NM, O'Valle F, Del Moral RG, García Estañ J, Vargas F & Osuna A. Effects of omapatrilat on blood pressure and renal injury in L-NAME and L-NAME plus DOCA-treated rats. American Journal of Hypertension 2003 16 33-38.
32. Sander M & Victor RG. Neural mechanisms in nitric-oxide-deficient hypertension. Current Opinion in Nephrology and Hypertension 1999 8 61-73.
33. Navarro J, Sanchez A, Saiz J, Ruilope LM, Garcia-Estan J, Romero JC, Moncada S & Lahera V. Hormonal, renal, and metabolic alterations during hypertension induced by chronic inhibition of NO in rats. American Journal of Physiology 1994 267 R1516-R1521.
34. Liu Y, Tsuchihashi T, Kigiyama S, Matsumura K, Abe I & Fujishima M. Central and peripheral mechanisms Involved in hypertension induced by chronic inhibition of nitric oxide synthase in rats. Journal of Hypertension 1998 16 1165-1173.
35. Baron AD, Zhu JS, Marshall S, Irsula O, Brechtel G & Keech C. Insulin resistance after hypertension induced by the nitric oxide synthesis inhibitor L-NMMA in rats. American Journal of Physiology 1995 269 E709-E715.
36. Lacolley PJ, Lewis SJ & Brody MJ. Role of sympathetic nerve activity in the generation of vascular nitric oxide in urethane-anesthetized rats. Hypertension 1991 17 881-887.
37. ω-nitro-L-arginine as affected by blockade of pressor mechanisms mediated by the sympathetic nervous system, angiotensin, prostanoids and vasopressin. Journal of Pharmacology and Experimental Therapeutics 1992 261 240-245.
38. Manning RD, Hu L & Williamson TD. Mechanisms involved in the cardiovascular-renal actions of nitric oxide inhibition. Hypertension 1994 23 951-956.
39. Scrogin KE, Hatton DC, Chi Y & Luft FC. Chronic nitric oxide inhibition with L-NAME: effects on autonomic control of the cardiovascular system. American Journal of Physiology 1998 274 R367-R374.
40. ω-nitro-L-arginine methyl ester. Hypertension 1997 30 64-70.
41. Fitzgerald SM & Brands MW, Hypertension in L-NAME-treated diabetic rats depends on an intact sympathetic nervous system. American Journal of Physiology 2002 282 R1070-R1076.
42. Wangensteen R, O'Valle F, Del Moral RG, Vargas F & Osuna A. Chronic alphal-adrenergic blockade improves hypertension and renal injury in L-NAME and low-renin L-NAME-DOCA hypertensive rats. Medical Science Monitor 2002 8 BR3 8-BR384.
43. Nylen A, Skagerberg G, Alm P, Larsson B, Holmqvist B & Anderson KE. Nitric oxide synthase in the hypothalamic paraventricular nucleus of the female rat; organization of spinal projections and coexistence with oxytocin or vasopressin. Brain Research 2001 908 10-24.
44. Wolff DJ & Gribin BJ. The inhibition of the constitutive and inducible nitric oxide synthase isoforms by indazole agents. Archives of Biochemistry and Biophysics 1994 311 300-306.
45. Moore PK & Bland-Ward PA. 7-Nitroindazole: an inhibitor of nitric oxide synthase. Methods in Enzymology 1996 268 393-398.
46. Ventura RR, Giusti-Paiva A, Gomes DA, Elias LL & Antunes-Rodrigues J. Neuronal nitric oxide synthase inhibition differentially affects oxytocin and vasopressin secretion in salt loaded rats. Neuroscience Letters 2005 379 75-80.
47. Xu L, Carter EP, Ohara M, Martin PY, Rogachev B, Morris K, Cadnapaphornchai M, Knotek M & Schrier RW. Neuronal nitric oxide synthase and systemic vasodilation in rats with cirrhosis. American Journal of Physiology 2000 279 F1110-F1115.
48. Alvarez G, Osuna A, Wangensteen R & Vargas F. Interaction between nitric oxide and mineralocorticoids in the long-term control of blood pressure. Hypertension 2000 35 752-757.
49. Deng LY, Thibault G & Schiffring EL. Effect of hypertension induced by nitric oxide synthase inhibition on structure and function of resistance arteries in the rat. Clinical and Experimental Hypertension 1993 15 527-537.
50. Vanhoutte PM, Lüscher TF & Gräser T. Endothelium-dependent contractions. Blood Vessels 1991 28 74-83.
51. Boulanger C & Lüscher TF. Release of endothelin from porcine aorta: Inhibition by endothelium-derived nitric oxide. Journal of Clinical Investigation 1990 85 587-590.
52. Vanhoutte PM, Auch-Schwelk W, Boulanger C, Janssen PA, Katusic ZS, Komori K, Miller VM, Schini VB & Vidal M. Does endothelin-1 mediate endothelium-dependent contractions during anoxia? Journal of Cardiovascular Pharmacology 1989 13 (Suppl 5) S124-S128.
53. Banting JD, Friberg P & Adams MA. Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction. Journal of Hypertension 1996 14 975-981.
54. Qiu C, Engels K & Baylis C. Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. Journal of the American Society of Nephrology 1995 6 1476-1481.
55. Richard V, Hogie M, Clozel M, Loffler BM & Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 1995 91 771-775.
56. Clozel M & Breu V. The role of ET(B) receptors in normotensive and hypertensive rats as revealed by the non-peptide selective ET(B) receptor antagonist Ro 46-8443. FEBS letters 1996 383 42-45.
57. Fujihara CK, De Nucci G & Zatz R. Do ETA receptors participate in the hemodynamic and renal effects of chronic nitric oxide blockade? Journal of Cardiovascular Pharmacology 1995 26 (Suppl 3) S462-S465.
58. Nakamura T, Ohyama Y, Masuda H, Kurasina T, Saito Y, Kato T, Sumino H, Sato K, Sakamaki T, Sasaki A & Nagai R. Chronic blockade of nitric oxide synthesis increases urinary endothelin-1 excretion. Journal of Hypertension 1997 15 373-381.
59. Moreau P, Takase H, Kung CF, Shaw S & Luscher TF. Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension. Hypertension 1997 29 763-769.
60. Sventek P, Turgeon A & Schiffrin EL. Vascular endothelin-1 gene expression and effect on blood pressure of chronic ETA endothelin receptor antagonism after nitric oxide synthase inhibition with L-NAME in normal rats. Circulation 1997 95 240-244.
61. Fernández-Rivas A, García-Estañ J & Vargas F. Effects of chronic increased salt intake on nitric oxide synthesis inhibition-induced hypertension. Journal of Hypertension 1995 13 123-128.
62. Miller WL, Redfield MM & Burnett CJ, Jr. Integrated cardiac, renal, and endocrine actions of endothelin. Journal of Clinical Investigation 1989 83 317-320.
63. Fortepiani LA, Janvier JJ, Ortíz MC, Atucha AM & García-Estañ J. Pressure natriuresis in nitric oxide deficient hypertensive rats: effects of endothelin blockade. Journal of Hypertension 1999 17 287-291.
64. Colin IM, Kopp P, Zbären J, Häberli A, Grizzle WE & Jameson LJ. Expression of nitric oxide synthase III in human thyroid follicular cells: evidence for increased expression in hyperthyroldism. European Journal of Endocrinology 1997 136 649-655.
65. Millatt LJ, Jackson R, William BC & Whitley GStJ. Nitric oxide stimulates cyclic GMP in human thyrocytes. Journal of Molecular Endocrinology 1993 10 163-169.
66. Rasmussen A, Di Marco R, Diamant M, Feldt-Rasmussen U & Bendtzen K. Nitric oxide production is not involved in the effects of interleukin-1β on cAMP, thyroglobulin and interleukin-6 in TSH-stimulated human thyroid cells. Autoimmunity 1994 19 239-245.
67. Kasai K, Hattori Y, Nakanishi N, Manaka K, Banba N, Motohashi S & Shimoda S. Regulation of inducible nitric oxide production by cytokines in human thyrocytes in culture. Endocrinology 1995 136 4261-4270.
68. Vargas F, Fernändez-Rívas A & Osuna A. Effects of methimazole in the early and established phases of L-NAME hypertension. European Journal of Endocrinology 1996 135 506-513.
69. Chappel CI, Rona G, Reversz C & Cahill J. Effect of propylthiouracil on adrenal-regeneration hypertension in the rat. Proceedings of the Society for Experimental Biology and Medicine 1958 98 23-26.
70. Salgado E. Effect of thyroidectomy on hypertension, nephrosclerosis and cardiac lesions produced by deoxyrorticosterone acetate (DCA) treatment in the rat. Endocrinology 1954 55 112-115.
71. Fregly MJ. Effects of propylthiouracil on development and maintenance of renal hypertension in rats. American Journal of Physiology 1958 194 149-154.
72. Rioux F & Berkowitz BM. Role of the thyroid gland in the development and maintenance of spontaneous hypertension in rats. Circulation Research 1977 40 306-312.
73. Rodger RL & McNeill JH. Antihypertensive effect of thyroidectomy in SHR: associated changes in heart performance. American Journal of Physiology 1986 250 600-605.
74. Rials SJ, Sullivan MM & Hansen JR. Effects of thyroidectomy on blood pressure of DOCA-hypertensive rats. Federation Proceedings 1982 41 1660.
75. Vargas F, García del Rio C, Luna JD, Haro JM & Osorio C. Studies on thyroid activity in deoxycorticosterone-salt and Goldblatt two-kidney, one-clip hypertensive rats. Acta Endocrinologica 1988 118 22-30.
76. Andrade J, Haro JM, Jódar E, Luna JD & Vargas F. Effects of methimazole on low renal mass hypertension: changes on blood pressure and pressor responsiveness to vasoconstrictors. Pharmacology 1992 44 315-323.
77. Andrade JL, Haro JM, Sabio JM, García del Rio C & Vargas F. Effects on renal function and digoxin-like immunoreactivity produced by methimazole in low-renal mass hypertension. Clinical and Experimental Hypertension. Part A 1992 14 1003-1016.
78. Vargas F, Castillo MA & Haro JM. Methimazole treatment reduces cardiac hypertrophy and mortality without a concomitant reduction in blood pressure in established Goldblatt two-kidney one clip hypertension. Experientia 1992 48 755-758.
79. Folkow B. Structural factor in primary and secundary hypertension. Hypertension 1990 16 89-101.
80. Bradley SE, Stéphan F, Coelho JB & Reville P. The thyroid and the kidney. Kidney International 1974 6 346-365.
81. Epstein FH. Estimating the effect of preventing obesity on total mortality and hypertension. International Journal of Obesity 1979 3 163-166.
82. Vargas F, Moreno JM, Rodríguez-Gómez I, Wangensteen R, Osuna A, Alvarez-Guerra M & García-Estañ J. Vascular and renal function in experimental thyroid disorders. European Journal of Endocrinology 2006 154 197-212.
83. Rodríguez-Gómez I, Sainz J, Wangensteen R, Moreno JM, Duarte J, Osuna A & Vargas F. Increased pressor ensitivity to chronic nitric oxide deficiency in hyperthyroid rats. Hypertension 2003 42 220-225.
84. García del Río C, Moreno MRR, Osuna A, Luna JD, García-Estañ J & Vargas F. Role of the renin-angiotensin system in the development of thyroxine-induced hypertension. European Journal of Endocrinology 1997 136 656-660.
85. García-Estañ J, Atucha N, Quesada T & Vargas F. Involvement of the renin-angiotensin in the reduced pressure-natriuresis response of hyperthyroid rats. American Journal of Physiology 1995 268 E897-E901.
86. Sabio JM, Garcia-Estañ J, García del Río C & Vargas F. Effects of N-nitro L-arginine metyl ester on the response to NaCl load in hyper and hypothyroid rats. Hormone and Metabolic Research 1994 26 409-412.
87. Chen YF. Sexual dimorphism of hypertension. Current Opinion in Nephrology and Hypertension 1996 6 181-185.
88. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001 37 1199-1208.
89. Sasaki T, Ohno Y, Otsuka K, Suzawa T, Suzuki H & Saruta T. Oestrogen attenuates the increases in blood pressure and platelet aggregation in ovariectomized and salt-loaded Dahl salt-sensitive rats. Journal of Hypertension 2000 18 911-917.
90. Chen Z, Yuhanna IS, Galcheva-Gargova ZI, Karas RH, Mendelsohn ME & Shaul PW Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. Journal of Clinical Investigation 1999 103 401-406.
91. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG & Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. PNAS 1994 91 5212-5216.
92. Sainz J, Osuna A, Wangensteen R, Luna JD, Rodríguez-Gómez I, Duarte J, Moreno JM & Vargas F. Role of sex, gonacedtomy and sex hormones in the development of nitric oxide inhibition-induced hypertension. Experimental Physiology 2004 89 155-162.
93. Verhagen AM, Attia DM, Koomans HA & Joles JA. Male gender increases sensitivity to proteinuria induced by mild NOS inhibition in rats: role of sex hormones. American Journal of Physiology 2000 279 F664-F670.
94. Reckelhoff JF, Hennington BS, Moore AG, Blanchard EJ & Cameron J. Gender differences in the renal nitric oxide (NO) system. Dissociation between expression of endothelial NO synthase and renal hemodynamic response to NO synthase inhibition. American Journal of Hypertension 1998 11 97-104.
95. Chen YF & Meng QC. Sexual dimorphism of blood pressure in spontaneously hypertensive rats is androgen dependent. Life Sciences 1991 48 85-96.
96. Reckelhoff JF, Zhang H, Srivastava K & Granger JR Gender differences in hypertension in spontaneously hypertensive rats: role of androgens and androgen receptor. Hypertension 1999 34 920-923.
97. Masubuchi Y, Kumai T, Uematsu A, Komoriyama K & Hirai M. Gonadectomy-induced reduction in blood pressure in adult spontaneously hypertensive rats. Acta Endocrinologica 1982 101 154-160.
98. Crofton JT, Share L & Brooks DP. Gonadectomy abolishes the sexual dimorphism in DOC-salt hypertension in the rat. Clinical and Experimental Hypertension. Part A 1989 11 1249-1261.
99. Malyusz M, Ehrens M & Wrigge P. Effects of castration on the experimental renal hypertension of the rat. Nephron 1985 40 96-99.
100. Crofton JT & Share L. Gonadal hormones modulate deoxycorti-costerone-salt hypertension in male and female rats. Hypertension 1997 29 494-499.
101. Sealey JE, Atlas SA & Laragh JH. Prorenin and other large molecular weight forms of renin. Endocrine Reviews 1980 1 365-391.
102. Nielsen AH, Johannessen A & Paulsen K. Inactive plasma renln exhibits sex difference in mice. Clinical science 1989 76 439-446.
103. Chen YF, Naftilan Al & Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension 1992 19 456-463.
104. Ellison KE, Ingelfinger JR, Pivor M & Dzau VJ. Androgen regulation of rat renal angiotensinogen messenger RNA expression. Journal of Clinical Investigation 1989 83 1941-1945.
105. Katz FH & Roper EF. Testosterone effect on renin system in rats. Proceedings of the Society for Experimentid Biology and Medicine 1977 155 330-333.
106. Davidoff M, Caffier H & Schiebler TH. Steroid hormone binding receptors in the rat Iddney. Histochemistry 1980 69 39-48.
107. Hollenberg NK, Coletti C & Passan D. Hypertension, volume and vasoconstriction: studies on the renal blood supply in SHR, WKY and DOCA-salt rats models. Hypertension Research 1992 15 3-11.
108. King AJ, Mercer P, Troy JL & Brenner BM. Endothelium-derived relaxing factor and the vascular reply to systemic hypertension. Journal of the American Society of Nephrology 1991 2 1072-1077.
109. Backman CS, jefries WB, Pettinger WA & Abel PW. Enhanced release of endothelium-derived relaxing factor in mincralocorti- cold hypertension. Hypertension 1992 20 304-313.
110. Hayakawa H, Hirata Y, Sizuki E, Kimura K, Kikuchi K, Nagano T, Hirobe M & Omata M. Long-term administration of L-Arginine improves nitric oxide release from kidneys in deoxycorticosterone acetate salt hypertensive rats. Hypertension 1994 23 752-756.
111. Selye H, Hall CE & Rowley EM. Malignant hypertension produced by treatment with desoxicorticosterone acetate and sodium chloride. Canadian Medical Association Journal 1943 49 88-92.
112. Vargas F, Casanova I, Haro JM, Luna JD & García del Río C. The handling of NaCl load in rats during DOCA-salt and Goldblatt 2 kydney-l clip, hypertension development. Revista Española de Fisiología 1988 44 185-190.
113. K-Laflamme A, Oster L, Cardinal R & de Champlain J. Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in dcoxycorticosterone acetate-salt hypertension. Canadian Journal of Physiology and Pharmacology 1998 76 665-675.
114. Erlich Y & Rosenthal T. Chronic hypertension leads to hyperinsulinemia in Sprague-Dawley rats treated with nitric oxide synthase inhibitor. American Journal of Hypertension 1998 11 1129-1133.
115. De Angelis Lobo d'Avila K, Gadonski G, Fang J, Dall'Ago P, Albuquerque VL, Peixoto LR, Fernandes TG & Irigoyen MC. Exercise reverses peripheral insulin resistance in trained L-NAME-hypertensive rats. Hypertension 1999 34 768-772.
116. Bursztyn M, Raz I, Mekler J & Ben-Ishay D. Effect of acute N-nitro-L-arginine methyl ester (L-NAME) hypertension on glucose tolerance, insulin levels, and [3H]-deoxyglucose muscle uptake. American Journal of Hypertension 1997 10 683-686.
117. Swislocki A, Eason T & Kaysen GA. Oral administration of the nitric oxide biosynthesis inhibitor, N-nitro-L-arginine methyl ester (L-NAME), causes hypertension, but not glucose intolerance or insulin resistance, in rats. American Journal of Hypertension 1995 8 1009-1014.
118. Nakaya Y, Ishimura. N, Takishita E & Takahashi A. Chronic feeding of a nitric oxide synthase inhibitor induces postprandial hypertriglyceridemia in type 2 diabetic model rats, Otsuka Long-Evans Tokushima Fatty rats, but not in nondiabetic rats. Metabolism: Clinical and Experimental 2002 51 702-707.
119. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazzini T, Nicod P, Thorens B & Scherrer U. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001 104 342-345.
120. Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, Nicod P, Thorens B & Scherrer U. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Medical Weekly 2003 133 360-363.
121. Cook S, Hugli O, Egli M, Menard B, Thalmann S, Sartori C, Perrin C, Nicod P, Thorens B, Vollenweider P, Scherrer U & Burcelin R. Partial gene deletion of endothelial nitric oxide synthase predisposes to exaggerated high-fat diet-induced insulin resistance and arterial hypertension. Diabetes 2004 53 2067-2072.
122. Claxton CR, Brands MW, Fitzgerald SM & Cameron JA. Inhibition of nitric oxide synthesis potentiates hypertension during chronic glucose infusion in rats. Hypertension 2000 35 451-456.
123. Bursztyn M, Mekler J, Peleg E & Bernheirn J. Subpressor dose of I-NAME unmask hypertensive effect of chronic hyperinsulinemia. Hypertension 2000 36 872-877.
124. Fang TC, Wu CC & Huang WC. Inhibition of nitric oxide synthesis accentuates blood pressure elevation in hyperinsulinemic rats. Journal of Hypertension 2001 19 1255-1262.
125. Lahera V, Salom MG, Fiksen-Olsen AM, Raij L & Romero JC. Effects of NG-monomethyl-L-arginine and L-arginine on acethylcholine renal response. Hypertension 1990 15 659-663.
126. Baylis C, Slangen B, Hussain S & Weaver C. Relatioship between basal NO release and cyclooxigenase products in the normal rat kidney. American Journal of Physiology 1996 271 R1327-RI334.
127. García-Estañ J, Navarro J, Atucha NM, Quesada T, Romero JC, Cachofeiro V & Lahera V. Chronic effect of nitric oxide and prostaglandin inhibition on pressure diuresis and natriuresis in rats. Kidney International 1996 49 S141-S143.
128. Da Cunha V, Rossoni LV, Oliveira PA, Poton S, Pretti SC, Vassallo DV & Stephanon I. Cycloxigenase inhibition reduces blood pressure elevation and vascular reactivity dysfunction caused by inhibition of nitric oxide synthase in rats. Clinical and Experimental Hypertension 2000 22 203-215.
129. Tomida T, Numaguchi Y, Nishimoto Y, Tsuzuki M, Hayashi Y, Imai H, Matsui H & Okumura K. Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2αformation in L-NAME treated rats. Journal of Hypertension 2003 21 601-609.
130. Muscara NM, Vergnolle N, Lovren F, Triggle CR, Elliot SN, Asfaha S & Wallace JL. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. British Journal of Pharmacology 2000 129 1423-1430.
131. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function.Physiological Reviews 2001 82 131-185.
132. Moreno C, Maier KG, Hoagland KM, Yu M & Roman RJ. Abnormal pressure-natriuresis in hypertension: Role of cytochrome P450 metabolites of arachidonic acid. American Journal of Hypertension 2001 14 90S-97S.
133. Alonso-Galicia M, Drummond RA, Reddy KK, Falck JR & Roman R.J. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension 1997 29 320-325.
134. Oyekan A & McGiff JC. Functional response of the rat kidney to inhibition of nitric oxide synthesis: role of cytochrome P-450-derived arachidonate metabolites. British Journal of Pharmacology 1998 125 1065-1073.
135. Sanchez-Mendoza MA, Martinez-Ayala SO, Hernandez-Hernandez JA, Zuñiga-Sosa L, Pastelin-Hernandez G & Escalante-Acosta BA. Participation of nitric oxide and arachidonle acid metabolites via cytochrome P-450 in the regulation of arterial blood pressure. Archivos de Cardiologia de México 2003 73 98-104.
136. Benter IF, Francis I, Cojocel C, Juggi JS, Yousif MH & Canatan H. Contribution of Cytochrome P450 metabolites of arachidonic acid to hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Autonomic & Autacoid Pharmacology 2005 25 143-154.
137. Huang H, Zhou Y, Raju VT, Du J, Chang HH, Wang CY, Brands MW, Falck JR & Wang MH. Renal 20-HETE inhibition attenuates changes in renal hemodynamics induced by L-NAME treatment in pregnant rats. American Journal of Physiology 2005 289 F1116-F1122.
138. Newaz M, Blanton A, Fidelis P & Oyekan AO. NAD(P)H oxidase/nitric oxide interaction in peroxisome proliferators activated receptor α (PPARα)-mediated cardiovascular effects. Mutation Research 2005 579 163-171.
139. Escalante B, Sacerdoti D, Davidian MM, Laniado-Schwartzman M & McGiff JC. Chronic treatment with tin normalizes blood pressure in spontaneously hypertensive rats. Hypertension 1991 17 776-779.
140. Shatara RK, Quest DW & Wilson TW. Fenofibrate lowers blood pressure in two genetic model of hypertension. Canadian Journal of Physiology and Pharmacology 2000 78 367-371.
141. Oyekan AO, McAward K, Conetta J, Rosenfeld L & McGiff JC. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. American Journal of Physiology 1999 276 R766-R775.
142. Ceccatelli S, Hulting AL, Zhang X, Gustafsson L, Villar M & Hokfelt T. Nitric oxide synthasc in the rat anterior pituitary gland and the role ofnitric oxide in regulation of luteinizing hormone secretion. PNAS 1993 90 11292-11296.
143. Duvilanski BH, Zambruno C, Seilicovich A, Piscra D, Lasaga M, Diaz MC, Belova N, Rettori V & McCann SM. Role of nitric oxide in control of prolactin release by the adenobypophysis. PNAS 1995 92 170-174.
144. Kato M. Involvement of nitric oxide in growth hormone (GH)-releasing hormone-induced GH secretion in rat pituitary cells. Endocrinology 1992 131 2133-2138.